Innovations for next-generation antibody-drug conjugates
Dr Amrik Basran and Dr Matt Vincent discuss various developments for antibody-drug conjugates to treat cancer.
List view / Grid view
Dr Amrik Basran and Dr Matt Vincent discuss various developments for antibody-drug conjugates to treat cancer.
Scientists observed that different cancers undergo the same genetic mutations at similar stages of evolution, the findings could become part of an ‘evolutionary rule book’ which would theoretically enable the prediction and prevention of cancer’s next evolutionary move.
A drug-like compound that can inhibit a key family of enzymes associated with several types of cancer has been developed and tested successfully in cells.
The prodrug developed by researchers caused long-term remission in all murine models of high-risk or drug-resistant cancers with fewer side-effects than a comparable drug.
Computational analysis has been used by researchers to examine 66 types of cancer and identify 568 genes that drive tumour development.
Researchers have treated diffuse intrinsic pontine glioma (DIPG), a fatal childhood brain cancer, in mice by targeting two metabolic pathways.
A study has identified more than 200 genes that drive the progression of glioblastoma and which the researchers say present drug targets.
Drug Target Review explores some of the newest oncologic drug targets, including those for glioblastoma, lung cancer and breast cancer.
A group of researchers has suggested that BBOX1 inhibitors could be used to treat triple negative breast cancer after showing success in mouse models.
Researchers reveal drugs inhibiting Neuropilin-1 (NRP1), a protein expressed on T cells, could improve the efficacy of immunotherapies.
Scientists have revealed that four molecules found in the Ceramaster patagonicus starfish show potency against cancer in cell lines.
A new study shows how the Bcl6 protein can regulate T follicular helper cells, presenting a target for autoimmune and infectious diseases.
Small molecules named CS1 (bisantrene) and CS2 (brequinar) have been developed by researchers to suppress the growth of tumours and have shown promise in mouse models.
By deleting the CISH gene from natural killer cells made from iPSCs, researchers say they have effectively treated leukaemia in vivo and in vitro.
Dr Jing Watnick discusses how lessons learnt from cancer immunotherapy treatments could be applied to the development of COVID-19 therapies.